Tharimmune announces $2.02 million private placement to advance development programs

Bridgewater, nj / accesswire / december 6, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. the agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock.
THAR Ratings Summary
THAR Quant Ranking